JAY VEGA: Open Payments
NPI 1457395659 · CUT OFF, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$649 in 38 payments from 14 companies in 2025. Trend: 2023 $518 · 2024 $606 · 2025 $649
Food & beverage: $649
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $174 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $98 |
| Vanda Pharmaceuticals Inc. | 4 | $97 |
| AstraZeneca Pharmaceuticals LP | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $34 |
| Novo Nordisk Inc | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
Products named: CAPLYTA, FANAPT, VRAYLAR, QULIPTA, Auvelity, Veozah, UBRELVY, Qelbree.
Industry payments across LA — which companies pay providers there.
